Pall Corporation


Hot off the Press!
Recently Published in BioProcess International’s Cell and Gene Therapies issue!

Get Your Copy Today!


Overcoming Obstacles in AAV Viral Vector Manufacturing

Rapidly growing interest in gene therapy has led to the need for more cost-effective and scalable viral-vector manufacturing platforms. Adeno-associated virus (AAV) has become a vector of choice because of its safety profile (nonpathogenic infection). In addition, AAV cannot replicate on its own and is not integrated directly into the host genome.

AAV manufacturing using human embryonic kidney (HEK) cells in either adherent or suspension mode includes several typical processing steps: cell expansion, plasmid transfection, viral vector production, cell lysis, purification, and fill and finish. Read More...

Fill out the Form to Download Full Copy.

Complete the Form to Get the Full Article

All fields required